Literature DB >> 33616647

Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials.

Ethan Basch1, Christina Yap2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33616647      PMCID： PMC8328974          DOI： 10.1093/jnci/djab017

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  11 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

3.  Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials.

Authors:  Peter C Trask; Amylou C Dueck; Elisabeth Piault; Alicyn Campbell
Journal:  Clin Trials       Date:  2018-09-19       Impact factor: 2.486

4.  Reliability of adverse symptom event reporting by clinicians.

Authors:  Thomas M Atkinson; Yuelin Li; Charles W Coffey; Laura Sit; Mary Shaw; Dawn Lavene; Antonia V Bennett; Mike Fruscione; Lauren Rogak; Jennifer Hay; Mithat Gönen; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2011-10-08       Impact factor: 4.147

5.  Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Arlene E Chung; Kimberly Shoenbill; Sandra A Mitchell; Amylou C Dueck; Deborah Schrag; Deborah W Bruner; Lori M Minasian; Diane St Germain; Ann M O'Mara; Paul Baumgartner; Lauren J Rogak; Amy P Abernethy; Ashley C Griffin; Ethan M Basch
Journal:  J Am Med Inform Assoc       Date:  2019-04-01       Impact factor: 4.497

6.  Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Authors:  Daniel Shepshelovich; Kate McDonald; Anna Spreafico; Albiruni R A Razak; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  Oncologist       Date:  2019-02-06

7.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Authors:  Erik K Fromme; Kristine M Eilers; Motomi Mori; Yi-Ching Hsieh; Tomasz M Beer
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

8.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

9.  Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Authors:  Ethan Basch; William A Wood; Deborah Schrag; Camelia S Sima; Mary Shaw; Lauren J Rogak; Mark G Kris; Marwan Shouery; Antonia Bennett; Thomas Atkinson; M Catherine Pietanza
Journal:  Clin Trials       Date:  2015-11-04       Impact factor: 2.486

10.  Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.

Authors:  Zachary W Veitch; Daniel Shepshelovich; Christina Gallagher; Lisa Wang; Albiruni R Abdul Razak; Anna Spreafico; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506
View more
  3 in total

1.  Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.

Authors:  Julia Lai-Kwon; Zhulin Yin; Anna Minchom; Christina Yap
Journal:  Cancer Med       Date:  2021-10-22       Impact factor: 4.452

2.  Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum.

Authors:  Julia Lai-Kwon; Alyssa M Vanderbeek; Anna Minchom; Olalekan Lee Aiyegbusi; Della Ogunleye; Richard Stephens; Melanie Calvert; Christina Yap
Journal:  Oncologist       Date:  2022-09-02       Impact factor: 5.837

3.  Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study.

Authors:  Ameeta Retzer; Stephanie Sivell; Hannah Scott; Annmarie Nelson; Helen Bulbeck; Kathy Seddon; Robin Grant; Richard Adams; Colin Watts; Olalekan Lee Aiyegbusi; Pamela Kearns; Samantha Cruz Rivera; Linda Dirven; Elin Baddeley; Melanie Calvert; Anthony Byrne
Journal:  BMJ Open       Date:  2022-09-30       Impact factor: 3.006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.